SymBio Pharmaceuticals Limited
SymBio Pharmaceuticals Limited engages in the and development, manufacturing and sales of pharmaceuticals and other related operations in Japan and internationally. It offers SyB V-1901, an antiviral drug for post-transplant infections, blood cancers and solid tumors, and neurodegenerative diseases; SyB L-1701, an RTD liquid formulation; SyB L-1702, an RI administration under the TREAKISYM name; … Read more
SymBio Pharmaceuticals Limited (SYMQY) - Total Assets
Latest total assets as of December 2025: $3.87 Billion USD
Based on the latest financial reports, SymBio Pharmaceuticals Limited (SYMQY) holds total assets worth $3.87 Billion USD as of December 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
SymBio Pharmaceuticals Limited - Total Assets Trend (2008–2025)
This chart illustrates how SymBio Pharmaceuticals Limited’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
SymBio Pharmaceuticals Limited - Asset Composition Analysis
Current Asset Composition (December 2025)
SymBio Pharmaceuticals Limited's total assets of $3.87 Billion consist of 98.9% current assets and 1.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 74.6% |
| Accounts Receivable | $259.85 Million | 6.7% |
| Inventory | $289.14 Million | 7.5% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2008–2025)
This chart illustrates how SymBio Pharmaceuticals Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: SymBio Pharmaceuticals Limited's current assets represent 98.9% of total assets in 2025, an increase from 97.3% in 2008.
- Cash Position: Cash and equivalents constituted 74.6% of total assets in 2025, up from 71.3% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2008.
- Asset Diversification: The largest asset category is inventory at 7.5% of total assets.
SymBio Pharmaceuticals Limited Competitors by Total Assets
Key competitors of SymBio Pharmaceuticals Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
SymBio Pharmaceuticals Limited - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - SymBio Pharmaceuticals Limited generates 0.35x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - SymBio Pharmaceuticals Limited is currently not profitable relative to its asset base.
SymBio Pharmaceuticals Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.96 | 6.43 | 5.01 |
| Quick Ratio | 2.74 | 6.12 | 4.05 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $2.54 Billion | $ 4.16 Billion | $ 4.00 Billion |
SymBio Pharmaceuticals Limited - Advanced Valuation Insights
This section examines the relationship between SymBio Pharmaceuticals Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.27 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | -22.1% |
| Total Assets | $3.87 Billion |
| Market Capitalization | $27.21 Million USD |
Valuation Analysis
Below Book Valuation: The market values SymBio Pharmaceuticals Limited's assets below their book value (0.01 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: SymBio Pharmaceuticals Limited's assets decreased by 22.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for SymBio Pharmaceuticals Limited (2008–2025)
The table below shows the annual total assets of SymBio Pharmaceuticals Limited from 2008 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $3.87 Billion | -22.11% |
| 2024-12-31 | $4.97 Billion | -39.19% |
| 2023-12-31 | $8.17 Billion | -21.69% |
| 2022-12-31 | $10.43 Billion | +23.43% |
| 2021-12-31 | $8.45 Billion | +34.72% |
| 2020-12-31 | $6.27 Billion | +18.98% |
| 2019-12-31 | $5.27 Billion | -15.47% |
| 2018-12-31 | $6.24 Billion | +46.73% |
| 2017-12-31 | $4.25 Billion | -38.18% |
| 2016-12-31 | $6.88 Billion | +38.00% |
| 2015-12-31 | $4.98 Billion | -33.13% |
| 2014-12-31 | $7.45 Billion | -3.03% |
| 2013-12-31 | $7.69 Billion | +39.71% |
| 2012-12-31 | $5.50 Billion | -24.17% |
| 2011-12-31 | $7.26 Billion | +70.22% |
| 2010-12-31 | $4.26 Billion | +0.05% |
| 2009-12-31 | $4.26 Billion | +183.82% |
| 2008-12-31 | $1.50 Billion | -- |